Seattle Genetics Inc. (NASDAQ:SGEN) has been assigned a consensus recommendation of “Hold” from the eighteen ratings firms that are currently covering the company. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $52.25.

Several equities research analysts recently weighed in on SGEN shares. Morgan Stanley started coverage on Seattle Genetics in a report on Wednesday, September 7th. They set an “overweight” rating and a $60.00 price target for the company. Leerink Swann reaffirmed a “buy” rating and set a $62.00 price target on shares of Seattle Genetics in a report on Friday, September 16th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $43.00 price target on shares of Seattle Genetics in a report on Monday, October 31st. Goldman Sachs Group Inc. downgraded Seattle Genetics from a “neutral” rating to a “sell” rating in a report on Friday, September 16th. Finally, RBC Capital Markets reaffirmed an “outperform” rating and set a $62.00 price target (up from $55.00) on shares of Seattle Genetics in a report on Monday, October 10th.

In related news, Director Felix Baker acquired 1,030,629 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The stock was purchased at an average price of $56.13 per share, for a total transaction of $57,849,205.77. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Clay B. Siegall sold 14,465 shares of Seattle Genetics stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $58.43, for a total value of $845,189.95. The disclosure for this sale can be found here. Corporate insiders own 33.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the company. Perigon Wealth Management LLC acquired a new stake in Seattle Genetics during the second quarter valued at approximately $1,212,000. State Board of Administration of Florida Retirement System boosted its stake in Seattle Genetics by 17.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 179,627 shares of the company’s stock valued at $7,258,000 after buying an additional 26,935 shares during the period. Emerald Acquisition Ltd. acquired a new stake in Seattle Genetics during the second quarter valued at approximately $16,220,000. Vanguard Group Inc. boosted its stake in Seattle Genetics by 2.6% in the second quarter. Vanguard Group Inc. now owns 7,110,502 shares of the company’s stock valued at $287,335,000 after buying an additional 178,403 shares during the period. Finally, Eqis Capital Management Inc. boosted its stake in Seattle Genetics by 4.6% in the second quarter. Eqis Capital Management Inc. now owns 38,087 shares of the company’s stock valued at $1,539,000 after buying an additional 1,658 shares during the period. Hedge funds and other institutional investors own 97.91% of the company’s stock.

WARNING: This piece of content was originally reported by Financial Market News and is owned by of Financial Market News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be viewed at http://www.financial-market-news.com/seattle-genetics-inc-sgen-receives-consensus-recommendation-of-hold-from-analysts/1209672/.

Shares of Seattle Genetics (NASDAQ:SGEN) opened at 66.38 on Friday. The stock’s 50 day moving average is $59.55 and its 200-day moving average is $48.78. The stock’s market cap is $9.40 billion. Seattle Genetics has a 12-month low of $26.02 and a 12-month high of $75.36.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings results on Thursday, October 27th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.06. Seattle Genetics had a negative return on equity of 16.27% and a negative net margin of 27.03%. The firm earned $106.30 million during the quarter, compared to the consensus estimate of $4.34 million. During the same period last year, the company earned ($0.21) earnings per share. The company’s revenue for the quarter was up 26.4% on a year-over-year basis. Equities analysts anticipate that Seattle Genetics will post ($0.95) EPS for the current fiscal year.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.